o

EUROPEAN MEDICINES AGENCY

SCIENCE MEDICINES HEALTH

EMA/136420/2013

EMEA/H/C/002660

EPAR summary for the public

Memantine Mylan

memantine

This is a summary of the European public assessment report (EPAR) for Memantine Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Memantine Mylan.

For practical information about using Memantine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

What is Memantine Mylan and what is it used for?

Memantine Mylan is a medicine used to treat patients with moderate to severe Alzheimer's disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour. It contains the active substance memantine.

Memantine Mylan is a 'generic medicine'. This means that Memantine Mylan is similar to a 'reference medicine' already authorised in the European Union (EU) called Ebixa. For more information on generic medicines, see the question-and-answer document here.

How is Memantine Mylan used?

Memantine Mylan is available as 10 mg and 20 mg tablets and can only be obtained with a prescription.

Treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease. Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Mylan by the patient.

Memantine Mylan should be given once a day at the same time every day. To prevent side effects, the dose of Memantine Mylan is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day. The tolerance and

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Memantine Mylan should be reassessed on a regular basis. The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.

For more information, see the package leaflet.

How does Memantine Mylan work?

The active substance in Memantine Mylan, memantine, is an antidementia medicine. The cause of Alzheimer's disease is unknown, but memory loss in the disease is believed to be due to a disturbance of message signals in the brain.

Memantine works by blocking special types of receptor called NMDA receptors to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another. Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease. In addition, overstimulation of the NMDA receptors may result in cell damage or death. By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer's disease.

How has Memantine Mylan been studied?

Because Memantine Mylan is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Ebixa. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Memantine Mylan?

Because Memantine Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

Why is Memantine Mylan approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine Mylan has been shown to have comparable quality and to be bioequivalent to Ebixa. Therefore, the CHMP's view was that, as for Ebixa, the benefit outweighs the identified risk. The Committee recommended that Memantine Mylan be approved for use in the EU.

What measures are being taken to ensure the safe and effective use of Memantine Mylan?

Safety information has been included in the summary of product characteristics and the package leaflet for Memantine Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.

Other information about Memantine Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Memantine Mylan on 22 April 2013.

The full EPAR for Memantine Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. For more information about treatment with Memantine Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

The full EPAR for the reference medicine can also be found on the Agency's website.

This summary was last updated in 04-2013.

Memantine Mylan

EMA/136420/2013

Page 3/3